Abstract:Objective To investigate the clinical effect of carvedilol combined with low-dose spironolactone in the prevention of rebleeding after endoscopic variceal treatment in the cirrhotic patients with variceal bleeding. Methods A total of 100 cirrhosis patients who were diagnosed as gastric fundal variceal bleeding and treated by gastroscopic variceal ligation and sclerotherapy in the Affiliated Hospital of North China University of Technology from January 2016 to January 2018 were selected. The selected patients were divided into observation group and control group randomly (n=50, each). The control group was treated with carvedilol and the observation group was treated with spironolactone and carvedilol. The therapeutic effect and the incidence of rebleeding were observed in two groups. Results The therapeutic effect of the observation group (33 cured, 15 effective, 2 ineffective) was better than that of the control group (20 cured, 25 effective, 5 ineffective), and the difference was significant（Z=2.623，P=0.009）. The portal vein main blood flow (Q_PV) and spleen thickness in the observation group were significantly lower than those in the control group (P<0.05). The incidence of rebleeding in the observation group within 24 months was significantly lower than that in the control group (P<0.05). There was no significant difference in rebleeding mortality between the two groups (P>0.05). There was no significant difference in the incidence of fatigue, dizziness, bradycardia, cough and hypotension between the two groups (P>0.05). Conclusion Carvedilol combined with low-dose spironolactone could reduce the risk of rebleeding in patients with cirrhotic bleeding after endoscopic varicose vein treatment, but it has no significant effect on reducing the mortality of rebleeding.